

Technology appraisal (TA)	Date of TA Release	Adherence of local formulary to NICE	
		Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2019-20			
TA625 - Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)	04/03/2020	No	Terminated appraisal
TA624 - Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis	19/02/2020	Yes	
TA623 - Patiromer for treating hyperkalaemia	13/02/2020	Yes	
TA622 - Sotagliflozin with insulin for treating type 1 diabetes	12/02/2020	Awaiting availability	Not currently available commercially. To be added to the formulary when commercially available
TA621 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer	22/01/2020	No	Not recommended
TA620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	15/01/2020	No	Not applicable to CWFT - Not commissioned
TA619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	15/01/2020	Yes	
TA618 - Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)	15/01/2020	No	Terminated appraisal
TA617 - Luspatorbopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	08/01/2020	No	Not applicable to CWFT - Not commissioned
TA616 - Cladribine for treating relapsing - remitting multiple sclerosis	19/12/2019	No	Not applicable to CWFT - Not commissioned
TA615 - Cannabidiol with clobazam for treating seizures associated with Lennox - Gastaut syndrome	18/12/2019	No	Not applicable to CWFT - Not commissioned
TA614 - Cannabidiol with clobazam for treating seizures associated with Dravet syndrome	18/12/2019	No	Not applicable to CWFT - Not commissioned
TA613 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy	20/11/2019	No	Not recommended
TA612 - Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	20/11/2019	Yes	
TA611 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	13/11/2019	No	Not applicable to CWFT - Not commissioned
TA610 - Pentosan polysulfate sodium for treating bladder pain syndrome	13/11/2019	Yes	
TA609 - Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (Terminated appraisal)	30/10/2019	No	Terminated appraisal
TA608 - Ibrutinib with rituximab for treating Waldenström's macroglobulinaemia (Terminated appraisal)	30/10/2019	No	Terminated appraisal
TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	17/10/2019	Yes	
TA606 - Lanadelumab for preventing recurrent attacks of hereditary angioedema	16/10/2019	No	Not applicable to CWFT - Not commissioned
TA605 - Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea	09/10/2019	Yes	
TA604 - Idelalisib for treating refractory follicular lymphoma	02/10/2019	No	Not recommended
TA603 - Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma	25/09/2019	No	Terminated appraisal
TA602 - Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma	25/09/2019	No	Terminated appraisal
TA601 - Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)	25/09/2019	No	Terminated appraisal

TA600 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer	11/09/2019	Yes	
TA599 - Sodium zirconium cyclosilicate for treating hyperkalaemia	04/09/2019	Yes	
TA598 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	28/08/2019	No	Not applicable to CWFT - Not commissioned
TA597 - Dapagliflozin with insulin for treating Type 1 Diabetes	28/08/2019	Yes	
TA596 - Risankizumab for treating moderate to severe plaque psoriasis	21/08/2019	Yes	
TA595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer	14/08/2019	Yes	
TA594 - Brentuximab vedotin for untreated advanced Hodgkin lymphoma (Terminated Appraisal)	14/08/2019	No	Terminated appraisal
TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	14/08/2019	Yes	
TA592 - Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma	07/08/2019	Yes	CWFT currently not commissioned. To challenge this decision with NHS England.
TA591 - Letermovir for preventing cytomegalovirus disease after a stem cell transplant	31/07/2019	No	Not applicable to CWFT - Not commissioned
TA590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis	31/07/2019	Yes	
TA589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity	24/07/2019	No	Not applicable to CWFT - Not commissioned
TA588 - Nusinersen for treating spinal muscular atrophy	24/07/2019	No	Not applicable to CWFT - Not commissioned
TA587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma	26/06/2019	Yes	
TA586 - Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib	26/06/2019	Yes	
TA585 - Ocrelizumab for treating primary progressive multiple sclerosis	12/06/2019	No	Not applicable - CWFT not a Specialist Neuroscience Centre
TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer	05/06/2019	Yes	
TA583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes	05/06/2019	Yes	
TA582 - Cabozantinib for previously treated advanced hepatocellular carcinoma	24/05/2019	No	Terminated appraisal
TA581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma	15/05/2019	Yes	
TA580 - Enzalutamide for hormone-relapsed non-metastatic prostate cancer	15/05/2019	No	Not recommended
TA579 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	08/05/2019	Yes	
TA578 - Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation	01/05/2019	Yes	
TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma	24/04/2019	Yes	
TA576 - Bosutinib for untreated chronic myeloid leukaemia (Terminated appraisal)	17/04/2019	No	Terminated appraisal
TA575 - Tildrakizumab for treating moderate to severe plaque psoriasis	17/04/2019	Yes	
TA574 - Certolizumab pegol for treating moderate to severe plaque psoriasis	17/04/2019	Yes	

TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	10/04/2019	Yes	
---	------------	------------	--